[{"id":"a59f2e7d-773d-4044-b655-2dd3f2f04a4f","acronym":"IMA950-106","url":"https://clinicaltrials.gov/study/NCT03665545","created_at":"2021-01-18T17:59:08.870Z","updated_at":"2024-07-02T16:35:58.554Z","phase":"Phase 1/2","brief_title":"Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma","source_id_and_acronym":"NCT03665545 - IMA950-106","lead_sponsor":"University Hospital, Geneva","biomarkers":" PD-L1","pipe":" | ","alterations":" HLA-A*02:01","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Hiltonol (poly-ICLC) • IMA950"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 10/25/2018","start_date":" 10/25/2018","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2022-12-26"}]